Cure Alzheimer’s Fund has been awarded the highest rating for sound fiscal management and commitment to accountability and transparency by Charity Navigator, the country’s largest and most-utilized independent evaluator of charities.
Cure Alzheimer's Fund (CAF) welcomes two new Scientific Advisory Board (SAB) members: Marc Tessier-Lavigne, Ph.D., president of The Rockefeller University, and former CAF Research Consortium member Robert C. Malenka, M.D., Ph.D., of Stanford University.
Meet Dr. Giuseppina Tesco, Cure Alzheimer’s Funded researcher, and assistant professor of neuroscience, Alzheimer’s Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine.
A Pittsburgh philanthropist and retired Mellon exec thinks so. In 1988, Jeffrey L. Morby left American Express to join the management team tapped to rescue the nearly bankrupt Mellon Bank. After helping turn Mellon around, he retired at 59, but Morby has hardly been wiling away the time.
When Maggie Campbell’s mother-in-law, Nancy Drapeau, was diagnosed with early-onset Alzheimer’s disease last summer at age 59, Campbell decided she wanted to do something to help. Originally from Omaha, Neb., Campbell is a bookbinder and letterpress printer in Brooklyn, N.Y.
From our 2011 Annual Report.
On behalf of the Board of Directors and the Research Consortium, we want to thank all the donors, researchers and academic institutional partners supporting Cure Alzheimer’s Fund research for your help in making 2011 such a successful science year. Guided by leading scientists in the field, Cure Alzheimer’s Fund-supported research continues to make breakthrough progress toward our goal of eradicating Alzheimer’s disease.
Rudy Tanzi, Chair, Cure Alzheimer's Fund Research Consortium comments here on the AP article appearing on this topic today:
Alzheimer’s is the sixth leading cause of death in the United States, but its most devastating effects can’t be counted. The disease steals away memories; it turns loved ones into strangers; it makes home unfamiliar and takes away all the things that define an individual. And, until recently, there’s been little hope of stopping its progress.
Cure Alzheimer’s Fund was founded to support cutting-edge, high-potential research to help the Alzheimer’s research community get on a smarter, faster trajectory toward a cure.
Consensus among Alzheimer’s researchers about the origins of the disease is growing. Most, including members of Cure Alzheimer’s Fund Research Consortium, agree that a combination of factors, beginning with the excessive build-up of the peptide Abeta42 triggering the development of tau tangles, nerve cell death, and inflammation are all required for Alzheimer’s pathology.
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.